Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab biomarker study in primary sclerosing cholangitis with concomitant inflammatory bowel disease
NL-OMON55753Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of vedolizumab in Primary Sclerosing Cholangitis (PSC) and inflammatory bowel disease (IBD) (4 arms), sponsored by Amsterdam University Medical Center. Started Jan 2018; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
Primary Sclerosing Cholangitis (PSC)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON55753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55753.